Trial Outcomes & Findings for Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive (NCT NCT02982018)

NCT ID: NCT02982018

Last Updated: 2018-07-19

Results Overview

Eyestrain related to glare was assessed at the 2-, 4-, 8- and 12- week follow-up visits using an 11-item questionnaire. This questionnaire assesses patient-experience attributes of soft contact lenses. Derived eyestrain related to glare scores using Item Response Theory (IRT) follow a normal distribution with a mean of 50 and a standard deviation of 10. Scores in this study ranged from 30 to 70. Lower scores indicate better performance. This questionnaire is still under development and the data collected is considered exploratory.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

133 participants

Primary outcome timeframe

Up to 12-Week Follow-up

Results posted on

2018-07-19

Participant Flow

A total of 133 subjects were enrolled into the study. Of the enrolled subjects 131 were dispensed study lenses and 2 subjects failed to meet the eligibility criteria. Of the dispensed subjects 123 completed the study and 8 subjects were discontinued.

Participant milestones

Participant milestones
Measure
Senofilcon A With New UV Blocker
Subjects that wore the senofilcon A with new UV blocker lens throughout the entire duration of the study.
Senofilcon A
Subjects that wore the senofilcon A lens throughout the entire duration of the study.
Overall Study
STARTED
67
64
Overall Study
COMPLETED
62
61
Overall Study
NOT COMPLETED
5
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Senofilcon A With New UV Blocker
Subjects that wore the senofilcon A with new UV blocker lens throughout the entire duration of the study.
Senofilcon A
Subjects that wore the senofilcon A lens throughout the entire duration of the study.
Overall Study
Incorrect Lens Dispensed
1
0
Overall Study
Protocol Violation
1
1
Overall Study
Adverse Event
1
1
Overall Study
Lens Discomfort
2
0
Overall Study
Withdrawal by Subject
0
1

Baseline Characteristics

Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Senofilcon A With New UV Blocker
n=67 Participants
Subjects that wore the senofilcon A with new UV blocker lens throughout the entire duration of the study.
Senofilcon A
n=64 Participants
Subjects that wore the senofilcon A lens throughout the entire duration of the study.
Total
n=131 Participants
Total of all reporting groups
Age, Continuous
31.2 Years
STANDARD_DEVIATION 8.15 • n=99 Participants
32.1 Years
STANDARD_DEVIATION 7.99 • n=107 Participants
31.6 Years
STANDARD_DEVIATION 8.02 • n=206 Participants
Sex: Female, Male
Female
45 Participants
n=99 Participants
47 Participants
n=107 Participants
92 Participants
n=206 Participants
Sex: Female, Male
Male
22 Participants
n=99 Participants
17 Participants
n=107 Participants
39 Participants
n=206 Participants
Race/Ethnicity, Customized
Asian
6 Participants
n=99 Participants
1 Participants
n=107 Participants
7 Participants
n=206 Participants
Race/Ethnicity, Customized
Black or African American
4 Participants
n=99 Participants
1 Participants
n=107 Participants
5 Participants
n=206 Participants
Race/Ethnicity, Customized
White
56 Participants
n=99 Participants
62 Participants
n=107 Participants
118 Participants
n=206 Participants
Race/Ethnicity, Customized
Other
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Up to 12-Week Follow-up

Population: Subjects that completed all study visits without a major protocol deviation.

Eyestrain related to glare was assessed at the 2-, 4-, 8- and 12- week follow-up visits using an 11-item questionnaire. This questionnaire assesses patient-experience attributes of soft contact lenses. Derived eyestrain related to glare scores using Item Response Theory (IRT) follow a normal distribution with a mean of 50 and a standard deviation of 10. Scores in this study ranged from 30 to 70. Lower scores indicate better performance. This questionnaire is still under development and the data collected is considered exploratory.

Outcome measures

Outcome measures
Measure
Senofilcon A With New UV Blocker (Test)
n=61 Participants
Subjects that wore the senofilcon A with new UV blocker lens for the first 12-weeks of the study.
Senofilcon A (Control)
n=59 Participants
Subjects that wore the senofilcon A lens for the first 12 weeks of the study.
Eyestrain Related to Glare
2-Week Follow-up
44.64 Units on a Scale
Standard Deviation 6.562
45.37 Units on a Scale
Standard Deviation 7.631
Eyestrain Related to Glare
4-Week Follow-up
46.40 Units on a Scale
Standard Deviation 7.489
44.59 Units on a Scale
Standard Deviation 7.300
Eyestrain Related to Glare
8-Week Follow-up
44.67 Units on a Scale
Standard Deviation 6.751
43.57 Units on a Scale
Standard Deviation 6.012
Eyestrain Related to Glare
12-Week Follow-up
43.66 Units on a Scale
Standard Deviation 5.921
44.02 Units on a Scale
Standard Deviation 7.687

PRIMARY outcome

Timeframe: Up to 12-Week Follow-up

Population: Subjects that completed all study visits without a major protocol deviation.

Distance logMAR Visual Acuity was assessed for each subject and eye at 2-, 4- 8- and 12-weeks. The average logMAR visual acuity for each lens and time point was reported. Lower values of logMAR indicate better vision.

Outcome measures

Outcome measures
Measure
Senofilcon A With New UV Blocker (Test)
n=122 Eyes
Subjects that wore the senofilcon A with new UV blocker lens for the first 12-weeks of the study.
Senofilcon A (Control)
n=118 Eyes
Subjects that wore the senofilcon A lens for the first 12 weeks of the study.
Distance Monocular logMAR Visual Acuity (VA)
2-Week Follow-up
-0.107 logMAR
Standard Deviation 0.0673
-0.080 logMAR
Standard Deviation 0.0663
Distance Monocular logMAR Visual Acuity (VA)
4-Week Follow-up
-0.106 logMAR
Standard Deviation 0.0713
-0.091 logMAR
Standard Deviation 0.0678
Distance Monocular logMAR Visual Acuity (VA)
8-Week Follow-up
-0.115 logMAR
Standard Deviation 0.0776
-0.0881 logMAR
Standard Deviation 0.0665
Distance Monocular logMAR Visual Acuity (VA)
12-Week Follow-up
-0.105 logMAR
Standard Deviation 0.0769
-0.0892 logMAR
Standard Deviation 0.0686

PRIMARY outcome

Timeframe: Up to 12-Week Follow-up

Population: All subjects that were dispensed at least one study lens.

Slit lamp findings were graded using a FDA Grade Scale, 0 = None, 1 = Slight, 2 = Moderate, 3 = Significant, 4 = Advanced. Measurements were taken in each subject eye at the initial visit, 2-4-8- and 12-week follow-ups. A new response variable was derived by dichotomizing the data as follows: 1 if a Grade 3or higher SLF was observed and 0 otherwise. The Percentage of eyes with Grade 3 or higher SLFs was reported for each lens and time point.

Outcome measures

Outcome measures
Measure
Senofilcon A With New UV Blocker (Test)
n=134 Eyes
Subjects that wore the senofilcon A with new UV blocker lens for the first 12-weeks of the study.
Senofilcon A (Control)
n=128 Eyes
Subjects that wore the senofilcon A lens for the first 12 weeks of the study.
Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings
2-Week Follow-up
0 Percentage of eyes
0 Percentage of eyes
Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings
4-Week Follow-up
0 Percentage of eyes
0 Percentage of eyes
Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings
8-Week Follow-up
0 Percentage of eyes
0 Percentage of eyes
Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings
12-Week Follow-up
0 Percentage of eyes
0 Percentage of eyes

SECONDARY outcome

Timeframe: Up to 12-Week Follow-up

Population: Subjects that completed all study visits without a major protocol deviation.

Contact lens wearing time (hours) was self-reported by each subject at the 2-, 4-, 8- and 12-week follow-ups. The average contact lens wearing time (hours) for each lens and time point was reported.

Outcome measures

Outcome measures
Measure
Senofilcon A With New UV Blocker (Test)
n=61 Participants
Subjects that wore the senofilcon A with new UV blocker lens for the first 12-weeks of the study.
Senofilcon A (Control)
n=59 Participants
Subjects that wore the senofilcon A lens for the first 12 weeks of the study.
Contact Lens Wearing Time
2-Week Follow-up
14.7 Hours
Standard Deviation 1.76
14.0 Hours
Standard Deviation 2.14
Contact Lens Wearing Time
4-Week Follow-up
14.5 Hours
Standard Deviation 2.03
14.2 Hours
Standard Deviation 2.14
Contact Lens Wearing Time
8-Week Follow-up
14.6 Hours
Standard Deviation 1.78
14.1 Hours
Standard Deviation 2.02
Contact Lens Wearing Time
12-Week Follow-up
14.7 Hours
Standard Deviation 1.67
14.3 Hours
Standard Deviation 1.83

SECONDARY outcome

Timeframe: Up to 12-Week Follow-up

Population: All subjects that were dispensed at least one study lens.

Symptoms, problems and complaints are subject reported and were collected for each subject eye at the 1-, 2-, 4-, 8- and 12-week follow-up evaluations. The data is reported as a binary outcome of yes if a subject experience a problem or complaint or no otherwise. Symptoms, problems and complaints include the following: Burning/Stinging, Itchiness/Scratchiness, Dryness, Lens Awareness, Grittiness/Foreign Body Sensation, Redness, Irritation/Discomfort, Cloudy/Blurry/Hazy, Variable Vision and Other The Percentage of subjects eyes with symptoms, problems or complaints was reported for each lens and time point.

Outcome measures

Outcome measures
Measure
Senofilcon A With New UV Blocker (Test)
n=134 Eyes
Subjects that wore the senofilcon A with new UV blocker lens for the first 12-weeks of the study.
Senofilcon A (Control)
n=128 Eyes
Subjects that wore the senofilcon A lens for the first 12 weeks of the study.
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints
2-Week Follow-up
15.2 Percentage of eyes
23.3 Percentage of eyes
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints
1-Week Follow-up
12.9 Percentage of eyes
13.3 Percentage of eyes
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints
4-Week Follow-up
14.1 Percentage of eyes
11.3 Percentage of eyes
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints
8-Week Follow-up
14.1 Percentage of eyes
16.9 Percentage of eyes
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints
12-Week Follow-up
12.7 Percentage of eyes
10.7 Percentage of eyes

Adverse Events

Senofilcon A With New UV Blocker

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Senofilcon A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

John Buch- SENIOR PRINCIPAL RESEARCH OPTOMETRIST

Johnson & Johnson Vision

Phone: 904 443-1707

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60